ETH-LAD

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search

Template:Short description Template:Cs1 config Template:Short description <templatestyles src="Infobox drug/styles.css"/> Script error: No such module "Infobox".Template:Template otherScript error: No such module "TemplatePar".{{Infobox drug/maintenance categoriesTemplate:Yesno | drug_name = | INN = | _drugtype =

| _has_physiological_data= | _has_gene_therapy=

| vaccine_type= | mab_type= | _number_of_combo_chemicals=Script error: No such module "ParameterCount". | _vaccine_data= | _mab_data= | _mab_vaccine_data= | _mab_other_data=212731CCN(C([C@@H]1C=C2C3=CC=CC4=C3C(C[C@H]2N(CC)C1)=CN4)=O)CC1S/C21H27N3O/c1-4-23(5-2)21(25)15-10-17-16-8-7-9-18-20(16)14(12-22-18)11-19(17)24(6-3)13-15/h7-10,12,15,19,22H,4-6,11,13H2,1-3H3/t15-,19-/m1/s1MYNOUXJLOHVSMQ-DNVCBOLYSA-NTemplate:StdinchiciteTemplate:Stdinchicite | _combo_data= | _physiological_data= | _clinical_data= Oral[1][2]Serotonin receptor agonist; Serotonergic psychedelic; Hallucinogen | _legal_data=NpSGClass AIllegal in France[3]

| _other_data=(6aR,9R)-N,N-diethyl-7-ethyl-4,6,6a,7,8,9-
hexahydroindolo-[4,3-fg]quinoline-9-carboxamide

| _image_0_or_2 = ETH-LAD_structure.png | _image_LR =

| _datapage = ETH-LAD (data page) | _vaccine_target=_type_not_vaccine | _legal_all=Class AIllegal in France[3] | _ATC_prefix_supplemental= | _has_EMA_link = | CAS_number=65527-62-0 | PubChem=44457783 | ChemSpiderID=21106300 | ChEBI= | ChEMBL=22694 | DrugBank= | KEGG= | _hasInChI_or_Key=yes | UNII=21Z2736X9Q | _hasJmol02 = |_hasMultipleCASnumbers = |_hasMultiplePubChemCIDs = |_hasMultipleChEBIs =

| _countSecondIDs=Script error: No such module "ParameterCount". | _countIndexlabels=Script error: No such module "ParameterCount". | _trackListSortletter= |QID = |QID2 = |Verifiedfields=verified |Watchedfields=verified |verifiedrevid=414446334}}

ETH-LAD, or ETHLAD, also known as 6-ethyl-6-nor-lysergic acid diethylamide (6-ethyl-6-nor-LSD), is a psychedelic drug of the lysergamide family related to lysergic acid diethylamide (LSD; also known as METH-LAD).[4][5] It is slightly more potent than LSD and is among the most potent psychedelics known.[6][4][7][2][8][9] The drug has been encountered as a novel designer drug in Europe.[10][11] In addition, a prodrug of ETH-LAD, 1P-ETH-LAD, has been developed and encountered.[12][13]

Use and effects

ETH-LAD is slightly more potent than LSD in both animals and humans.[4][7][6][5][14][9] It is about 1.6- to 2.3-fold more potent than LSD in rodent drug discrimination tests.[7][6][5][9] The drug's human dose range is 20 to 150Script error: No such module "String".μg orally, compared to a range of 50 to 200Script error: No such module "String".μg given for LSD, and it is said to be roughly twice as potent as LSD in humans.[1][2][4][8][9] As such, ETH-LAD is one of the most potent serotonergic psychedelics in humans known, if not the most potent known psychedelic.[6][4][7][8][9] Moreover, it has been said that LSD can no longer be considered the most potent psychedelic.[15] ETH-LAD's duration is 8 to 12Script error: No such module "String".hours as with LSD.[1]

The qualitative effects of ETH-LAD are similar to those of LSD.[7][1] In a limited number of anecdotal reports collected and published by Alexander Shulgin in TiHKAL however, ETH-LAD was described as more gentle and as less pushy, demanding, and aggressive than LSD, but also as having less of LSD's sparkle.[1] ETH-LAD was said to have a greatly modified degree of visual distortion relative to LSD as well.[1]

Interactions

Script error: No such module "Labelled list hatnote".

Pharmacology

ETH-LAD acts as a serotonin receptor agonist, including of the serotonin 5-HT2A receptor.[16][17] It shows greater potency and efficacy as a serotonin 5-HT2A receptor agonist than LSD in vitro.[16] In addition to the serotonin 5-HT2A receptor, the drug binds with high affinity to the serotonin 5-HT1A and 5-HT2C receptors.[16] Like LSD, ETH-LAD also binds with lower affinity to the dopamine D1, D2, D3, D4, and D5 receptors.[16][18]

ETH-LAD shows psychedelic-like effects in animals, specifically rodent drug discrimination tests.[7][6][14] Similarly to LSD, ETH-LAD shows moderate anti-inflammatory effects in preclinical research, but with slightly higher potency.[17]

Chemistry

Script error: No such module "Labelled list hatnote".

According to Alexander Shulgin, ETH-LAD may be chemically unstable in solution.[1]

Analogues of ETH-LAD include LSD, PRO-LAD, FLUORETH-LAD, and AL-LAD among others. In addition, ALD-52, LSZ, and LSM-775 are analogues of ETH-LAD. 1P-ETH-LAD, a prodrug of ETH-LAD, has been developed and encountered.[12][13]

History

ETH-LAD was first described in the scientific literature by at least 1976.[19] Subsequently, its preclinical pharmacology was studied and described by Andrew J. Hoffman and David E. Nichols in 1985.[14] ETH-LAD's properties and effects in humans were assessed by Alexander Shulgin.[8][9] These were reported via personal communication by Nichols in 1986[9][15] and later described by Alexander Shulgin himself in a 1994 literature review[8] and in his 1997 book TiHKAL (Tryptamines I Have Known and Loved).[1] ETH-LAD was encountered as a novel designer drug in Europe by 2016.[10][11]

Society and culture

Legal status

United Kingdom

On June 10, 2014, the United Kingdom Advisory Council on the Misuse of Drugs (ACMD) recommended that ETH-LAD be specifically named in the UK Misuse of Drugs Act as a class A drug despite not identifying it as ever having been sold or any harm associated with its use.[20] The UK Home office accepted this advice and announced a ban of the substance to be enacted on 6 January 2015.[21]

Switzerland

ETH-LAD is illegal in Switzerland as of December 2015.[22]

References

<templatestyles src="Reflist/styles.css" />

  1. ↑ a b c d e f g h Script error: No such module "citation/CS1".
  2. ↑ a b c Script error: No such module "citation/CS1".
  3. ↑ Script error: No such module "citation/CS1".
  4. ↑ a b c d e Script error: No such module "citation/CS1".
  5. ↑ a b c Script error: No such module "citation/CS1".
  6. ↑ a b c d e Script error: No such module "Citation/CS1".
  7. ↑ a b c d e f Script error: No such module "citation/CS1".
  8. ↑ a b c d e Script error: No such module "Citation/CS1".
  9. ↑ a b c d e f g Script error: No such module "Citation/CS1".
  10. ↑ a b Script error: No such module "citation/CS1".
  11. ↑ a b Script error: No such module "Citation/CS1".
  12. ↑ a b Script error: No such module "Citation/CS1".
  13. ↑ a b Script error: No such module "Citation/CS1".
  14. ↑ a b c Script error: No such module "Citation/CS1".
  15. ↑ a b Script error: No such module "citation/CS1".
  16. ↑ a b c d Template:Cite thesis
  17. ↑ a b Script error: No such module "Citation/CS1".
  18. ↑ Script error: No such module "Citation/CS1".
  19. ↑ Script error: No such module "Citation/CS1".
  20. ↑ Script error: No such module "citation/CS1".
  21. ↑ Script error: No such module "citation/CS1".
  22. ↑ Script error: No such module "citation/CS1".

Script error: No such module "Check for unknown parameters".

External links

Template:Psychedelics Template:Serotonin receptor modulators Template:Dopamine receptor modulators Script error: No such module "Navbox".

Retrieved from "http://debianws.lexgopc.com/wiki143/index.php?title=ETH-LAD&oldid=3096102"